European Urology Open Science (Feb 2023)

Combination of the PARP inhibitor olaparib with the vascular disrupting agent NOV202 reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts

  • A.S. Bjartell,
  • E. Sereti,
  • S. Evans Axelsson

Journal volume & issue
Vol. 48
p. S22

Abstract

Read online

No abstracts available.